Increased Risk of End-Stage Renal Disease (ESRD) Requiring Chronic Dialysis is Associated With Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Nationwide Case-Crossover Study

Yu-Kang Chang, PhD, Jia-Sin Liu, MS, Yueh-Han Hsu, MD, Der-Cherng Tarng, MD, PhD, and Chih-Cheng Hsu, MD, DrPH

Abstract: It is known that many medical adverse events can be caused by nonsteroidal anti-inflammatory drugs (NSAIDs); however, epidemiologic evidence has not granted an affirmative relationship between NSAID use and the risk of end-stage renal disease (ESRD). We aimed to investigate the relationship in a Chinese population between short-term NSAID use and development of ESRD requiring chronic dialysis.

A retrospective case-crossover design was used in this study. Using the Taiwanese National Health Insurance database, we identified 109,400 incident chronic ESRD patients with dialysis initiation from 1998 to 2009. For each patient, we defined the case period as 1 to 14 days and the control period as 105 to 118 days, respectively, before the first dialysis date. The washout period was 90 days between the case and control period. Detailed information about NSAID use was compared between the case and control periods. We calculated odds ratios (ORs) and their 95% confidence intervals (CIs) using a conditional logistic regression model.

NSAID use was found to be a significant risk factor associated with dialysis commencement. The adjusted OR was 2.73 (95% CI: 2.62–2.84) for nonselective NSAIDs and 2.17 (95% CI: 1.83–2.57) for celecoxib. The OR reached 3.05 for the use of acetic acid derivatives.

INTRODUCTION

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most common medications used by the general population for acute or chronic soreness and inflammation. It has been estimated that >30 million people worldwide take NSAIDs every day.1 The systemic adverse consequences caused by NSAIDs—such as acute myocardial infarction,2–4 stroke,5 gastrointestinal bleeding,6–8 and renal cancer9—are well known. Regarding the NSAID-related renal effects, some harmful pathologic dynamics have been recognized, which include sodium and water retention,10,11 hyperkalemia,12 acute renal injury,13 interstitial nephritis,14 nephrotic syndrome,15 papillary necrosis,16 and developmental defects17; however, the relationship between NSAID use and development of end-stage renal disease (ESRD) requiring dialysis has not been well established in epidemiologic studies. In a case–control study, Perneger et al18 showed a cumulative dose of >5000 pills containing NSAIDs was associated with an increased risk of long-term dialysis. Schneider et al19 found that both selective and nonselective NSAIDs had a significant association with acute renal failure in a nested case–control study; however, many more studies have reported conflicting results. Murray et al20 indicated regular analgesic consumption, including the use of NSAIDs, did not increase the risk of ESRD development. Ibanez et al21 could not link the risk of ESRD to long-term use of NSAIDs. In a recent study, Michielsen et al22 also could not affirm the association between analgesic nephropathy and high use of nonphenacetin analgesics in ESRD patients. The inconsistent results may derive from some inherent limitations for the case–control studies: the researchers could not completely guarantee comparability between the case and control groups; the recall bias pertaining to lifelong NSAID use in interview surveys could also significantly jeopardize accurate estimate of renal impacts caused by NSAID use. In this study,
we used a case-crossover study design to eliminate any undetectable residual confounding factors to delineate the risk of NSAID use in the development of ESRD requiring chronic dialysis. Furthermore, we used a reliable National Health Insurance (NHI) dataset to precisely calculate NSAID dosage and define the time at which dialysis commenced. We aimed to estimate the unbiased risk encountered by NSAID users for the initiation of dialysis.

MATERIALS AND METHODS

Data Source

The NHI program, which enrolls about 99% of Taiwan’s population of 23 million, has been the country’s core infrastructure of the health care system since 1995. The Taiwan National Health Insurance Research Database (TNHIRD), derived from the reimbursement claims within the NHI program, is considered one of most reliable national medical utilization databases in the world. From the TNHIRD, we retrieved as our study subjects a cohort who received at least 3-month dialysis treatment (chronic dialysis) during 1998 to 2009. To search for comorbidities that the study subjects might have, we also studied the TNHIRD with antecedent data from January 1, 1997. This study has been approved by the institutional review board of the National Health Research Institutes in Taiwan.

Design and Study Subjects

We used a population-based, case-crossover study design to evaluate the relationship between short-term NSAID use and the risk of developing ESRD requiring chronic dialysis. The subject-as-own-control research design, in which the frequency of NSAID exposure in the case and control periods were retrospectively compared, has advantages in reducing recall bias, selection bias, and undetectable residual confounding factors because the exposure information in the case and control periods is provided by the same person. If the exposure time is short (2 weeks in the current study), bias from misclassification and time-varying exposure status can further be reduced.

We identified all patients who started chronic dialysis from 1998 to 2009 based on the dialysis treatment codes of the TNHIRD. The date of the first dialysis was defined as the index date. There were 109,400 subjects selected in the current study.

Data on Drug Exposure

The drug exposures of interest in this study were collected from the reimbursement claims recorded in the TNHIRD. We divided the nonselective NSAIDs into 5 classifications, based on their mechanism of action or chemical structure: aspirin, propionic acid, acetic acid derivatives, enolic acid derivatives, and anthranilic acid derivatives. Several commonly used NSAIDs were then classified accordingly: the propionic acid category included ibuprofen, naproxen, ketoprofen, fenbufen, alminofen, and flurbiprofen; the acetic acid derivatives included indomethacin, alclofenac, diclofenac, etodolac, ketorolac, and sulindac; the enolic acid derivatives included meloxicam, piroxicam, tenoxicam, and nimesulide; and the anthranilic acid derivatives included flufenamic acid, mefenamic acid, niflumic acid, tiaprofenic acid, and tolfenamic acid. For the selective NSAIDs, we included only 2 drugs used in the Taiwan market: celecoxib and rofecoxib. From the pharmacy dispensing records of the TNHIRD, we collected information about the type of drugs, dosage, date of prescription, total number of drug pills, and days of drug supply. We used the WHO standard methods to calculate the defined daily dose of NSAIDs taken by each study subject to assess their drug exposure in the case and control periods. Then we further stratified those who had taken NSAIDs according to quartile of defined daily dose per day and different cumulative exposure time (1–3, 4–6, 7–10, or 11–14 days) for subgroup analyses.

Comorbidies and Concomitant Medications

We collected patients’ information on sex, age, date of dialysis commencement, and comorbidities from the TNHIRD. The following chronic comorbidities were defined as covariates, if the subjects, prior to dialysis commencement, had at least 1 hospitalization or 2 ambulatory visits within 1 year due to any of the following illnesses: diabetes mellitus (International Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-CM] code 250), hypertension (ICD-9-CM codes 401–405), cardiovascular disease (ICD-9-CM codes 410–414), gout (ICD-9-CM codes 274.9), cancer (ICD-9-CM codes 140–208), stroke (ICD-9-CM codes 430–438), and myocardial infarction (ICD-9-CM codes 410). Two acute illnesses—urinary tract infection (ICD-9-CM codes 599.0) and pneumonia (ICD-9-CM codes 486)—were identified in the case period. Other concomitant drug use collected in this study included acetaminophen, anti-hypertensive agents (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blocker, calcium channel blockers, and diuretics), antidiabetic drugs (biguanides, sulfonylureas, and insulin), and statins. We further collected information on contrast media and aminoglycosides use in the case period to minimize confounding effects caused by these drugs.

STATISTICAL ANALYSIS

For each study subject, the case period was defined as 1 to 14 days before the index date and the control period as 105 to 118 days before the index date, by which we set 90 days between the case and control periods as a washout period to minimize drugs’ residual effects. The cumulative dosages of NSAID prescriptions during the case and control periods were respectively calculated. We compared the odds of NSAID use between the case and control periods to estimate the crude odds ratio (OR) and 95% confidence interval (CI). In the multiple analyses, conditional logistic regressions were performed to assess excess risk of starting dialysis for NSAID use after adjusting for sex, age, comorbidity, year of dialysis commencement, and concomitant medications used. To evaluate the possible dose–response effect, we also separately estimate the adjusted OR for those with different exposure dosage (by quartile) and different exposure duration (1–3, 4–6, 7–10, or 11–14 days). In the sensitivity analyses, we repeated our conditional logistic analyses by stratifying study subjects according to their sex (male, female), age (<40, 40–64, ≥65), year of dialysis commencement (1998–2003, 2004–2009), comorbidities including diabetes, hypertension, gout, cardiovascular disease, cancer, stroke, and myocardial infarction, and some acute events—including intensive care unit (ICU) admission, contrast media use, urinary tract infection, and pneumonia—during the case period. We also evaluated the robustness of our results by defining different washout period (60, 90, 120, and 180 days). All p values were 2-sided, with a P value < 0.05 considered to have reached a significance level. All analyses were conducted using SAS version 9.2 (SAS Institute Inc, Cary, NC).
RESULTS

We identified 100,490 patients with dialysis commencement from 1998 to 2009. The baseline characteristics of the study subjects are summarized in Table 1. Approximately half of the selected patients were male and >65 years. Diabetes (50.1%) and hypertension (65.2%) were the 2 main comorbidities the study subjects had prior to development of dialysis, followed by cardiovascular disease (32.7%) and myocardial infarction (23.9%). Table 2 presents the use of concomitant medications during the case period (1–14 days before the index date) and the control period (105–118 days before the index date). A similar pattern of drug prescription for diabetes and hypertension could be seen in the case and control periods. Nevertheless, the use of contrast media during the case period was significantly more frequent than in the control period (13.1% vs 1.8%). Disproportional distribution was also found for aminoglycosides use (5.6% vs 3.5%).

Table 3 shows the crude and adjusted ORs for the development of ESRD requiring chronic dialysis under the use of NSAIDs. The adjusted ORs of overall, selective, and nonselective NSAID use were 2.72 (95% CI: 2.60–2.82), 1.70 (95% CI: 1.51–1.91), and 2.73 (95% CI: 2.62–2.84), respectively. For individual classes of nonselective NSAIDs, the highest adjusted OR was 3.05 (95% CI: 2.87–3.23) for acetic acid derivatives use; the risks of use of enolic acid derivatives, propionic acid, anthranilic acid derivatives, and aspirin were 1.91 (95% CI: 1.74–2.11), 1.68 (95% CI: 1.55–1.82), 1.65 (95% CI: 1.49–1.79), and 1.53 (95% CI: 1.41–1.69), respectively. The adjusted ORs of selective NSAIDs for celecoxib and rofecoxib were 2.17 (95% CI: 1.83–2.57) and 1.65 (95% CI: 1.51–1.91), respectively. The highest adjusted OR found the parenteral NSAID use (OR: 8.66, 95% CI: 6.12–20.19).

Figure 1 shows dose–response renal risks in the overall, selective, and different nonselective NSAID classes. Compared with the nonusers, the renal risk was gradually increased with higher NSAID cumulative exposure dosage (Panel A) and days (Panel B) (except the anthranilic acid derivatives, P for trend were all significant in different NSAID drug classes). The detailed information about dose–response effects were shown in supplemental Table 1, http://links.lww.com/MD/A417 and supplemental Table 2, http://links.lww.com/MD/A417. The estimated effects of NSAID use on development of chronic dialysis were similar to the main findings, irrespective of whether the washout period was redefined (supplemental Table 3, http://links.lww.com/MD/A417).

In sensitivity analyses (Figure 2), NSAIDs, both selective and nonselective, were associated with a higher risk of developing ESRD requiring dialysis; this was consistent across different patient characteristics, comorbidities, and acute events in the case period. Generally speaking, the risk of NSAID-related initiation of dialysis was higher in men, younger people, and those without chronic diseases such as diabetes, hypertension, chronic kidney disease, and gout. In contrast, those who suffered from acute illness in the case period—such as ICU hospitalization, contrast media use, urinary tract infection, and pneumonia—were more sensitive to the harmful effects of NSAID use. Higher dialysis risks were noted for concurrent use of NSAIDs during the acute illness stage.

DISCUSSION

This is the first study investigating the risk of development of ESRD requiring chronic dialysis for short-term exposure to NSAIDs. The current study demonstrated that most selective or nonselective NSAIDs were associated with higher risk of dialysis commencement. The use of parenteral forms of NSAIDs could even increase the dialysis risk by up to 8 times. We used a case-crossover study design to resolve common limitations encountered in traditional case–control studies. Different from other studies in which lifelong exposures were often inquired, this study could accurately assess impacts of immediate NSAID use on renal function deterioration. Our results clearly show that NSAID exposure could be the last straw triggering the necessities for dialysis commencement. Clinicians should be cautious about prescribing any NSAIDs to vulnerable ESRD patients.
In a nested case–control study, Schneider et al found that the elderly in the Canadian Healthcare Program who were the current NSAID users were more likely to be hospitalized for acute renal failure; however, the effects of renal risk would be diminished after >30 days without NSAID prescription. Huerta et al used the British General Practice Research Database to conduct another nested case–control study, resulting in similar conclusions: compared with nonusers, current NSAID users increased their risk of acute renal failure by 3.2-fold; but this hazard ratio declined and became insignificant once NSAID use had been stopped for >30 days. Apart from being consistent with these previous findings, the current study is the first study to further demonstrate that short-term NSAID use could cause not only transient acute renal failure but also permanent kidney damage requiring dialysis, a final detrimental renal outcome.

We found that selective and nonselective NSAID users alike were both prone to develop ESRD requiring chronic dialysis; but the risk of nonselective NSAID users (adjusted OR: 2.72) was greater than selective NSAID users (adjusted OR: 1.70). We also reported a higher adjusted OR for celecoxib (2.73) than for rofecoxib (1.68). As a result, patients with a dual diagnosis of chronic renal failure and acute myocardial infarction or stroke strengthening concerns about the detrimental renal impact of parenteral NSAIDs. Furthermore, in spite of the theoretically equal efficacy between the oral and parenteral forms of various NSAIDs, both patients and physicians still believed parenteral forms were more potent than the oral forms. Thus, prescription of parenteral NSAIDs is common among general practitioners and in emergency departments. Our study provides empirical evidence for greater precaution in prescribing parenteral NSAIDs.

The results shown in the current study also indicate that the renal risk caused by short-term NSAID use was more likely to occur when patients were vulnerable, such as being admitted to ICU (adjusted OR: 5.89), having a urinary tract infection (adjusted OR: 4.09), or having pneumonia (adjusted OR: 5.86). The detrimental renal damage might have been preventable if NSAIDs had not been concurrently used.

### TABLE 3. Risk of Chronic Dialysis Associated With Current Use of Selective and Nonselective NSAIDs

| Types | No of Patients Use During Case Period But Not Control Period | No of Patients Use During Control Period But Not Case Period | Crude OR (95% CI) | Adjusted OR (95% CI) |
|-------|-------------------------------------------------------------|-------------------------------------------------------------|------------------|---------------------|
| Overall | 32,478 | 6226 | 5.22 (5.08–5.36) | 2.72 (2.60–2.82) |
| Nonselective NSAIDs | 32,159 | 6013 | 5.35 (5.20–5.50) | 2.73 (2.62–2.84) |
| Aspirin | 14,025 | 3271 | 4.29 (4.13–4.45) | 1.53 (1.41–1.69) |
| Propionic acid | 5698 | 2209 | 2.58 (2.46–2.71) | 1.68 (1.55–1.82) |
| Acetic acid derivatives | 16,702 | 3238 | 5.16 (4.97–5.36) | 3.05 (2.87–3.23) |
| Enolic acid derivatives | 4422 | 1513 | 2.92 (2.76–3.10) | 1.91 (1.74–2.11) |
| Anthranilic acid derivatives | 3493 | 1619 | 2.16 (2.03–2.29) | 1.65 (1.49–1.79) |
| Selective NSAIDs | 1415 | 517 | 2.74 (2.47–3.03) | 1.70 (1.51–1.91) |
| Celecoxib | 1424 | 448 | 3.18 (2.86–3.53) | 2.17 (1.83–2.57) |
| Rofecoxib | 192 | 77 | 2.49 (1.91–3.25) | 1.65 (1.23–3.35) |
| Routes | | | | |
| IV only | 314 | 22 | 14.27 (9.26–21.99) | 8.66 (6.12–20.19) |
| IV/oral | 26,698 | 5439 | 4.91 (4.77–5.05) | 2.60 (2.45–2.80) |
| Oral only | 5736 | 765 | 7.50 (6.95–8.09) | 3.74 (3.52–4.69) |
| Types | | | | |
| Nonselective only | 28,203 | 5885 | 4.79 (4.66–4.93) | 2.74 (2.60–2.89) |
| Both selective/nonselective | 1978 | 330 | 5.99 (5.33–6.73) | 2.23 (2.21–3.37) |
| Selective only | 909 | 747 | 1.22 (1.1–1.34) | 1.18 (1.03–1.41) |

Adjusted OR was based on conditional logistic regression adjusted for confounding variables including the use of acetaminophen, ACEI/ARB, beta-blocker, CCB, diuretics, biguanides, sulfonylureas, insulin, statin, contrast media, and aminoglycosides. ACEI = angiotensin-converting enzyme inhibitors, ARB = angiotensin receptor blockers, CCB = calcium channel blockers, CI = confidence interval, IV = intravenous, NSAIDs = nonsteroidal anti-inflammatory drugs, OR = odds ratio.

* P < 0.05.
FIGURE 1. Risks of end-stage renal disease requiring chronic dialysis associated with short-term exposure of nonsteroidal anti-inflammatory drugs, stratified by different exposure dosage A, and B, duration. (Q1: \( \leq 0.25 \), Q2: 0.26–0.50, Q3:0.51–0.75, Q4: >0.75 define daily dose, *\( P < 0.05 \)). NSAIDs = nonsteroidal anti-inflammatory drugs, OR = odds ratio.
STUDY LIMITATIONS

The results presented in the current study should be interpreted with caution due to the following limitations. First, in examining drug exposure we did not account for over-the-counter NSAID use; but the nondifferential misclassification of exposure status would probably bias the results toward the null hypothesis. Second, the case-crossover design is a retrospective observational study, so we cannot make causal inferences. Third, there are no behavioral or lifestyle profiles in the TNHIRD, so we could not control for confounding factors such as body mass index, cigarette smoking, alcohol consumption, and clinical biomarkers; however, these unmeasurable confounding factors would keep consistent during the relatively short time between the case and control period, minimizing the limitations inherent in research using healthcare insurance databases. Fourth, our study evaluated the risk of short-term NSAID use; the results might not be generalizable to the risk of long-term NSAID use. Fifth, due to availability of data sources, we could only assess renal risk of NSAID use for those under chronic dialysis, but we believed consistent results could be seen in patients with acute kidney injury.

CONCLUSIONS

Use of selective COX inhibitors or nonselective NSAIDs, for even as little as 2 weeks, may be able to deteriorate vulnerable people’s renal function to a level requiring dialysis. Health providers should be cautious about prescribing NSAIDs, particularly in a parenteral form, to any patient at risk of renal function impairment.

REFERENCES

1. Singh G, Triadalopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl. 1999;56:18–24.
2. Scott PA, Kingsley GH, Smith CM, et al. Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis. 2007;66:1296–1304.
3. Garcia Rodriguez LA, Gonzalez-Perez A, Bueno H, et al. NSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studies. PLoS One. 2011;6:e16780.
4. Shau WY, Chen HC, Chen ST, et al. Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan’s National Health Insurance claims database and review of current evidence. BMC Cardiovasc Dis. 2012;12:4.
5. Chang CH, Shau WY, Kuo CW, et al. Increased risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study. Stroke. 2010;41:1884–1890.
6. Chang CH, Lin JW, Chen HC, et al. Non-steroidal anti-inflammatory drugs and risk of lower gastrointestinal adverse events: a nationwide study in Taiwan. Gut. 2011;60:1372–1378.
7. Lee YC, Chang CH, Lin JW, et al. Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients. *Liver Int.* 2012;32:859–866.

8. Coxib and traditional NSAID Trialsist’s (CNT) Collaboration Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. *Lancet*. 2013;382:769–779.

9. Cho E, Curhan G, Hankinson SE, et al. Prospective evaluation of analgesic use and risk of renal cell cancer. *Arch Intern Med.* 2011;171:1487–1493.

10. Hermann M, Ruschitzka F. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk. *Int Med J.* 2006;36:308–319.

11. Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. *Am J Med.* 1999;107:658–70S discussion 708–715.

12. Lafrance JP, Miller DR. Dispensed selective and nonselective nonsteroidal anti-inflammatory drugs and the risk of moderate to severe hyperkalemia: a nested case-control study. *Am J Kidney Dis.* 2012;60:82–89.

13. Moon KW, Kim J, Kim JH, et al. Risk factors for acute kidney injury by non-steroidal anti-inflammatory drugs in patients with hyperuricaemia. *Rheumatology (Oxford).* 2011;50:2278–2282.

14. Leonard CE, Freeman CP, Newcomb CW, et al. Proton pump inhibitors and traditional nonselective anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. *Pharmacoepidemiol Drug Saf.* 2012;21:1155–1172.

15. Kuroki A, Akizawa T. Drug-induced nephrotic syndrome. *Nihon Rinsho.* 2012;70 (suppl 6):419–422.

16. Stern AW, Ritchey JW, Hall B, et al. Nonsteroidal anti-inflammatory drug-associated renal papillary necrosis in a white-tailed deer (*Odocoileus virginianus*). *J Vet Diagn Invest.* 2010;22:476–478.

17. Zhang MZ, Wang JL, Cheng HF, et al. Cyclooxygenase-2 in rat nephron development. *Am J Physiol.* 1997;273:F994–1002.

18. Perneger TV, Whetton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. *N Engl J Med.* 1994;331:1675–1679.

19. Schneider V, Levesque LE, Zhang B, et al. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. *Am J Epidemiol.* 2006;164:881–889.

20. Murray TG, Stolley PD, Anthony JC, et al. Epidemiologic study of regular analgesic use and end-stage renal disease. *Arch Intern Med.* 1983;143:1687–1693.

21. Ibanez L, Morlans M, Vidal X, et al. Case-control study of regular analgesic and nonsteroidal anti-inflammatory use and end-stage renal disease. *Kidney Int.* 2005;67:2393–2398.

22. Michielsen P, Heinemann L, Mihatsch M, et al. Non-phenacetin analgesics and analgesic nephropathy: clinical assessment of high users from a case-control study. *Nephrol Dial Transplant.* 2009;24:1253–1259.

23. Lin CC, Lai MS, Syu CY, et al. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. *J Formos Med Assoc.* 2005;104:157–163.

24. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. *Am J Epidemiol.* 1991;133:144–153.

25. Maclure M, Fireman B, Nelson JC, et al. When should case-only designs be used for safety monitoring of medical products? *Pharmacoepidemiol Drug Saf.* 2012;21 (suppl 1):50–61.

26. Zhao SZ, Reynolds MW, Lejkowith J, et al. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. *Clin Ther.* 2001;23:1478–1491.

27. Maclure M, Mittleman MA. Should we use a case-crossover design? *Ann Rev Public Health.* 2000;21:193–221.

28. Roach RE, Siegerink B, Lijfering WM. Case-crossover studies: Research into risk factors with the patient as his or her own control. *Ned Tijdschr Geneesk.* 2013;157:A5896.

29. Huerta C, Castellsague J, Varas-Lorenzo C, et al. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. *Am J Kidney Dis.* 2005;45:531–539.

30. Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. *Am J Med.* 2001;111:64–67.

31. Gruberg L, Mehran R, Dangas G, et al. Acute renal failure requiring dialysis after percutaneous coronary interventions. *Catheter Cardiovasc Interv.* 2001;52:409–416.

32. Rocha JL, Fernandez-Alonso J. Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib. *Lancet.* 2001;357:1946–1947.

33. Perazella MA, Eras J. Are selective COX-2 inhibitors nephrotoxic? *Am J Kidney Dis.* 2000;35:937–940.

34. Ahmad SR, Kortepeker C, Brinker A, et al. Renal failure associated with the use of celecoxib and rofecoxib. *Drug Safety.* 2002;25:537–544.

35. Feldman HI, Kimmnn JL, Berlin JA, et al. Parenteral ketorolac: the risk for acute renal failure. *Ann Int Med.* 1997;126:193–199.

36. Buckley MM, Brogden RN. Ketorolac: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. *Drugs.* 1990;39:86–109.

37. Wright JM, Price SD, Watson WA. NSAID use and efficacy in the emergency department: single doses of oral ibuprofen versus intramuscular ketorolac. *Ann Pharmacother.* 1994;28:309–312.

38. Turturro MA, Paris PM, Seaberg DC. Intramuscular ketorolac versus oral ibuprofen in acute musculoskeletal pain. *Am J Kidney Dis.* 1995;26:117–120.

39. Schwartz NA, Turturro MA, Isvan DJ, et al. Patients’ perceptions of route of nonsteroidal anti-inflammatory drug administration and its effect on analgesia. *Acad Emerg Med.* 2000;7:857–861.

40. Arora S, Wagner JG, Herbert M. Myth: parenteral ketorolac provides more effective analgesia than oral ibuprofen. *CJEM.* 2007;9:30–32.